Welcome to our dedicated page for CareDx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CareDx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CareDx's regulatory disclosures and financial reporting.
CareDx Director Peter Maag has reported the sale of 10,000 shares of common stock at a weighted average price of $19.242 per share on June 17, 2025. The transaction was executed pursuant to a Rule 10b5-1 trading plan established on August 21, 2024.
The shares were sold in multiple transactions with prices ranging from $18.80 to $19.52. Following the reported transaction, Maag continues to hold 318,846 shares directly.
- Transaction Type: Sale (S)
- Ownership Type: Direct (D)
- Total Transaction Value: Approximately $192,420
- Trading Plan: Executed under pre-established 10b5-1 plan
This insider sale represents approximately 3% of Maag's direct holdings in CareDx and was conducted under a predetermined trading plan, which helps avoid concerns about insider trading.
CareDx, Inc. (CDNA) – Form 144 filing discloses a proposed sale of 10,570 common shares through Morgan Stanley Smith Barney on the NASDAQ. The shares, acquired as restricted stock units on 14 Jun 2025, carry an aggregate market value of $206,326.40, implying an indicative price of roughly $19.53 per share. The transaction is slated to occur on or about 18 Jun 2025. According to the filing, no other sales were made in the past three months, and the sale represents only ~0.02 % of the 55.68 million shares outstanding, suggesting minimal dilution or market impact. The filer certifies awareness of no undisclosed material adverse information and may be relying on a Rule 10b5-1 trading plan. Relationship to the issuer and filer identity were not provided in the excerpt.